Showing results (431-440 of 552) with videos related to
Sort By:
Pageof 56
Dermatitis : Contact, Atopic, Occupational, Drug|February 19, 2025
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD RegistryDawn Z Eichenfield, Keith D Knapp, Ami Claxton, et al.Experimental Dermatology|May 18, 2021
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe diseaseJonathan T Sims, Ching-Yun Chang, Richard E Higgs, et al.Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.American Journal of Clinical Dermatology|October 21, 2025
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III TrialsTiffany Mayo, Jonathan I Silverberg, April Armstrong, et al.The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.Dermatology and Therapy|June 23, 2025
Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Stephan Weidinger, Eric L Simpson, et al.Journal of the American Academy of Dermatology|January 9, 2023
Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapiesRobert Sidbury, Ali Alikhan, Lionel Bercovitch, et al.Journal of the American Academy of Dermatology|November 9, 2023
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapiesDawn M R Davis, Aaron M Drucker, Ali Alikhan, et al.Journal of the American Academy of Dermatology|February 8, 2018
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyEmma Guttman-Yassky, Jonathan I Silverberg, Osamu Nemoto, et al.Journal of the American Academy of Dermatology|January 31, 2024
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trialEric L Simpson, Jonathan I Silverberg, Margitta Worm, et al.Pageof 56